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Abstract Attempts to demonstrate (rans-activation activity by 
the Drosophila myb gene product (D-Myb) have been unsuccess-
ful so far. We demonstrate that co-transfection of Schneider cells 
with a plasmid expressing the Drosophila homologue of 
transcriptional co-activator CBP (dCBP) results in trans-
activation by D-Myb. Using this assay system, the functional 
domains of D-Myb were analyzed. Two domains located in the 
N-proximal region, one of which is required for DNA binding 
and the other for dCBP binding, are both necessary and sufficient 
for frans-activation. In this respect, D-Myb is similar to c-Myb 
and A-Myb, but different from mammalian B-Myb. These 
results shed light on how the myb gene diverged during the course 
of evolution. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Many studies indicate that the vertebrate c-myb nuclear 
proto-oncogene is primarily involved in the maintenance of 
the proliferative state of immature hematopoietic cells [1,2]. 
On the other hand, two other vertebrate members of the myb 
gene family, A-myb and TS-myb [3], are thought to be impor-
tant for cellular proliferation in testis and in more ubiquitous 
cell lineages, respectively [4-6]. The c-myb gene is highly con-
served in many species. Although the myb gene has diverged 
into three genes in vertebrates, Drosophila possesses only one 
myb gene [7,8]. Comparison of the Drosophila myb gene prod-
uct (D-Myb) with the three vertebrate myb-reVdted proteins 
(c-Myb, A-Myb, and B-Myb) indicates the presence of two 
homologous regions, the N-terminal DNA-binding domain, 
which recognizes the specific DNA sequence, AACNG [9-
11], and the C-terminal conserved region. The existence of 
these homologies suggests that D-Myb also functions as a 
transcriptional activator by binding to the same recognition 
sequence as vertebrate Myb. So far, however, frans-activation 
by D-Myb has not been successfully demonstrated, and the 
reason for this is unknown [12]. Molecular studies on the 
three vertebrate Myb proteins indicated that both c-Myb 
and A-Myb can fraws-activate in all cells examined, and that 
the two domains responsible for DNA binding and transcrip-
tional activation are sufficient for this purpose [10,13,14]. In 
contrast, B-Myb has ^raws-activating activity only in a limited 
number of types of cells, and the C-terminal region conserved 
between c-myb, A-myb, and B-myb (CR for conserved region) 
in the B-Myb molecule is necessary for this activity [15]. Since 
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the Drosophila system has the advantage of being accessible to 
genetic analysis, a study of D-Myb in this system would be 
expected to yield valuable information about the signal trans-
duction pathway involving D-Myb and the molecular mecha-
nism that regulates Myb activity. Due to the lack of an assay 
system to measure D-Myb activity, the analyses of the func-
tional domains of D-Myb and the comparison of these do-
mains with those of vertebrate Myb proteins have been im-
possible. 
Recently, we demonstrated that the transcriptional co-acti-
vator CBP is necessary for frans-activation by mammalian 
c-Myb [16]. CBP directly binds to the transcriptional activa-
tion domain of c-Myb, which is rich in acidic amino acids, 
and mediates trans-activation by c-Myb. CBP was originally 
identified as a co-activator for the transcriptional activator, 
CREB [17]. CBP possesses intrinsic histone acetyltransferase 
activity [18], and also binds to another histone acetyl trans-
ferase, P/CAF [19], suggesting that the CBP/PCAF complex 
contributes to promoter activation by altering or disrupting 
inhibitory chromatin structure. Recent studies indicate that 
CBP is also utilized by a multitude of other transcriptional 
regulators including c-Jun [20], c-Fos [21], c-Myb [16,22], nu-
clear hormone receptors [23,24], MyoD [25], and Stat2 [26]. 
CBP also functions as a bridge between these regulators and 
the basal transcriptional machinery by binding to the basal 
transcriptional factor TFIIB [27] and the RNA polymerase II 
holoenzyme complex [28]. In mammals, the CBP gene family 
has two members, CBP and p300 [29], the functions of which 
are indistinguishable [30,31]. Like the myb gene, the CBP gene 
is also conserved in many species including mammals and 
C. elegans [32]. The Drosophila homolog of CBP (dCBP) 
has been recently identified and shown to have striking ho-
mology with mouse CBP [33]. These observations suggest that 
the Myb-CBP interaction is conserved in Drosophila. 
We report here that the recently identified dCBP binds to 
D-Myb. Using the co-transfection assay with the dCBP ex-
pression plasmid, we demonstrate ft-aws-activation by D-Myb, 
and identify the functional domains involved in this activity. 
2. Materials and methods 
2.1. Plasmids 
The D-myb cDNA clones were isolated from the Drosophila cDNA 
library prepared from 0-6 h embryos using the PCR-amplified DNA 
fragment which was based on the published sequence of D-myb. The 
plasmid pGEM-D-myb, which was used to synthesize D-Myb by in 
vitro transcription/translation, was constructed by insertion of ~D-myb 
cDNA into the BamHl-Sall sites of the pGEM vector (Promega). 
Using the appropriate enzyme sites, we constructed plasmids for the 
synthesis of various forms of D-myb. The CAT reporter plasmid, 
pADHCAT6MBS-I, was constructed by inserting six tandem repeats 
of the mouse c-Myb-binding site MBS-I identified in the SV40 en-
hancer into the Xbal site of pAdhCAT which contains the Drosophila 
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alcohol dehydrogenase promoter [34]. The plasmid pA5c-D-myi used 
to express D-myb in the cultured cells was constructed by inserting the 
D-myb cDNA into pUchs-neoAct5c downstream of the Drosophila 
actin 5c promoter [35]. The plasmids encoding various forms of 
D-myb were constructed from pA5cD-myb using the appropriate en-
zyme sites. The plasmid used to express GST-dCBP in bacteria, the 
plasmid used to express dCBP in cultured cells, the control effector 
plasmid pA5cO, and the internal control plasmid pA5c-|3-gal were 
described previously [33]. 
2.2. In vitro binding assays 
GST pull-down assays were performed as described [16]. 
2.3. CAT co-transfection assays 
Transfections in Schneider cells were done with the reporter plas-
mid pADCAT6MBS-I containing the six tandem repeats of the 
c-Myb-binding site MBS-I. Transfection assays were performed as 
described by Nocera and Dawid [36]. The amount of lysate used for 
the CAT assays was normalized by measuring (5-galactosidase activity 
resulting from the internal control plasmid pA5c-p-gal. All CAT co-
transfection experiments were repeated at least three times. Typical 
results are shown in the figures. The differences between each set of 
experiment did not vary by more than 30%. 
3. Results 
3.1. Binding of D-Myb to dCBP 
To test for direct binding between D-Myb and dCBP, we 
examined whether in vitro translated D-Myb could interact 
with the GST-dCBP fusion protein (Fig. 1). Protein affinity 
resins of GST alone or GST-dCBP fusion protein (amino 
acids 781-1159) were used as ligands. This 379-amino-acid 
region of dCBP contains a 85-amino-acid region that is highly 
conserved between murine CBP, dCBP, and other members of 
the CBP family [33]. This region should be sufficient for bind-
ing D-Myb, as a 201-amino-acid region of mouse CBP con-
taining this highly conserved region can efficiently bind to 
mouse c-Myb [16]. The full-length form of D-Myb was syn-
thesized using an in vitro transcription/translation system, and 
mixed with the GST alone or GST-dCBP affinity resin. Ap-
proximately 12% of the input D-Myb bound to the GST-
dCBP resin (Fig. IB, lanes 1 and 6), in contrast to the 
GST-resin where no binding was detected (data not shown). 
D-Myb bound to the GST-dCBP resin without pretreatment 
with PKA, and PKA treatment did not increase the efficiency 
of D-Myb binding to dCBP (data not shown). By using the 
GST fusion proteins containing various regions of dCBP, we 
confirmed that D-Myb binds only to the 379-amino-acid re-
gion of dCBP described above (data not shown). 
To examine whether dCBP interacts with the acidic region 
of D-Myb located downstream of the DNA-binding domain, 
we used deletion mutants of D-Myb in the binding assay (Fig. 
1). The results of the binding assays indicate that dCBP binds 
to the region between amino acids 230 and 416 of D-Myb 
which contains the putative acidic activation domain. 
3.2. Trans-activation by D-Myb in the presence of dCBP 
To examine whether dCBP functions as a co-activator of 
D-Myb, we employed CAT co-transfection assays in Droso-
phila Schneider cells (Fig. 2). The plasmid pADHCAT6MBS-
I, which contains six tandem repeats of the mouse c-Myb-
binding site MBS-I linked to the Drosophila alcohol dehydro-
genase promoter, was used as the reporter plasmid. In the 
absence of dCBP, an increasing amount of D-Myb expression 
plasmid did not activate CAT expression from this reporter 
plasmid (Fig. 2A). This result is consistent with a previous 
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Fig. 1. Binding of D-Myb to dCBP. A: Schematic representation of 
the results of the binding analyses. On the top, the three regions in 
D-Myb comprising the DNA-binding domain, the dCBP-binding 
domain identified here, and the region conserved among the differ-
ent members of the myb gene family, are indicated. The structures 
of the various forms of D-Myb used are shown below. Mutants 
that bind to dCBP are indicated by stippled bars, and a mutant 
that does not bind by a open bar. The results of binding assays de-
scribed below are indicated on the right. The relative binding activ-
ities of the mutants are designated by ++, +, and —, which indicate, 
respectively, 12-16%, 5-7%, and less than 0.5% of binding of the in-
put protein. Less than 0.5% of the input D-Myb proteins bound to 
the control GST resin (data not shown). B: Results of the binding 
analyses. The GST-dCBP fusion protein contained the 379-amino-
acid region (amino acids 781-1159). In lanes 1-5, the Sepharose res-
in containing GST-dCBP were mixed with various derivatives of the 
in vitro translated [35S]D-Myb as indicated above lane. After wash-
ing, the bound proteins were released and analyzed on 10% SDS-
PAGE followed by autoradiography. In lanes 6-10, the various de-
rivatives of D-Myb designated above each lane were synthesized in 
vitro and directly analyzed by 10% SDS-PAGE. The amount of 
[35S]D-Myb used for the input lane was 10% of that used for the 
binding assays. 
report of another group showing that the /raws-activating ca-
pacity of D-Myb can not be detected under these conditions 
[12]. The experiment was repeated again, but this time increas-
ing amounts of the dCBP expression plasmid were co-trans-
fected in the presence or absence of the D-Myb expression 
plasmid (Fig. 2B). Co-transfection of increasing amounts of 
the dCBP expression plasmid increased the level of Jnms-acti-
vation by a maximum of 6.8-fold. This level was achieved at a 
ratio of 15 (xg of dCBP expression plasmid to 3 \ig of D-Myb 
expression plasmid. In the control experiment without any 
D-Myb expression plasmid, the addition of the dCBP expres-
sion plasmid did not affect the level of CAT activity at all. 
Thus, dCBP potentiates D-Myb-induced frvms-activation. 
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Fig. 2. Potentiation of D-Myb-dependent /rans-activation by dCBP. A: D-Myb fails to Zrans-activate without the dCBP expression plasmid. A 
mixture of 3 itg of the CAT reporter plasmid pADHCAT6MBS-I, increasing amounts of the D-Myb expression plasmid \>act5c-D-myb or the 
control plasmid pact5c0 lacking the D-Myb-coding region, and 1 |xg of the internal control plasmid pact5c-p-gal was transfected into Schneider 
cells. The total amount of DNA was adjusted to 19 u.g by adding the control plasmid pact5c0. CAT assays were done, and a set of typical re-
sults is shown on the left. The degree of /rani-activation (compared to samples without the c-Myb expression plasmid) is shown on the right. 
B: Effect of dCBP on D-Myb-dependent frarcs-activation. A mixture of 3 ug of a CAT reporter plasmid pADHCAT6MBS-I, increasing 
amounts of the dCBP expression plasmid pact5c-dCBP, 3 |xg of the D-Myb expression plasmid pact5c-D-m_y6 or the control plasmid pact5c0 
lacking the D-Myb coding region, and 1 ug of the internal control plasmid pact5c-|3-gal was transfected into Schneider cells. The total amount 
of DNA was adjusted to 19 |xg by adding the control plasmid pact5c0. The CAT assays were done, and the results are indicated as described 
above. 
3.3. Functional domains of D-Myb 
Using the co-transfection assays with the dCBP expression 
plasmid, we then attempted to identify the regions of D-Myb 
required for trans-activation (Fig. 3). The effector plasmids 
used to express various forms of D-Myb were individually 
co-transfected with the reporter plasmid pADH6MBS-I and 
the dCBP expression plasmid, and CAT activity was meas-
ured. The amino acid sequence of DNA-binding domain in 
the N-terminal region is conserved between mammalian 
c-Myb and D-Myb, and this region contains the nuclear local-
ization signals [10]. Consistent with this, all forms of D-Myb 
used here were localized in the nuclei, and the level of each 
form was almost similar by judging with the Western blotting 
(data not shown). The results obtained using a series of 
C-truncated D-Myb mutants indicate that the N-terminal 
416-amino-acid region, which contains the DNA-binding do-
main and the dCBP-binding domain, is both necessary and 
sufficient for frans-activation by D-Myb. These results show 
that the dCBP-binding domain located downstream of the 
DNA-binding domain functions as a transcriptional activation 
domain. In addition, our results show that the C-terminal re-
gion located downstream of the dCBP-binding domain, which 
contains a region conserved among members of the myb gene 
family, does not affect the frans-activating activity of D-Myb. 
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Fig. 3. Domain analyses of D-Myb. A: Schematic representation of the CAT assays. On the top, the three regions in D-Myb are indicated. 
The structures of various forms of D-Myb are shown below. Mutants that possess and lack the frosts-activating capacity are indicated by 
stippled bars, and open bars, respectively. The degree of frans-activation by each mutant is indicated on the right. B: Results of CAT assays. 
7><ms-activation of various forms of D-Myb were examined as described in Fig. 2. A mixture of 7 |xg of a CAT reporter plasmid pADH-
CAT6MBS-I, 9 ug of the dCBP expression plasmid pact5c-dCBP, 4 ug of the D-Myb expression plasmid encoding the protein indicated above 
each lane or the control plasmid pact5c0 lacking the D-Myb coding region, and 2 ug of the internal control plasmid pact5c-(i-gal was trans-
fected into Schneider cells. The total amount of DNA was adjusted to 22 ug by adding the control plasmid pact5c0. The CAT assays were 
done, and the results are indicated as described above. 
4. Discussion 
By realizing co-transfection assays with the dCBP expres-
sion plasmid, we have been able to demonstrate D-Myb-in-
duced fraws-activation in Schneider cells. Multiple parameters 
including the endogenous levels of transcription factors and 
their associated co-factors are known to affect the level of 
fraro-activation observed in co-transfection assays using spe-
cific cell lines. In the case of mammals, many cell lines are 
currently available and thus, the optimal cell line for the co-
transfection assays can be chosen. However, only a limited 
number of Drosophila cell lines such as Schneider and Kc 
cell lines have been established. So far, we and other groups 
have not been succeeded to demonstrate fr<ms-activation by 
D-Myb in these cell lines [12], probably as a result of limiting 
amounts of dCBP. A reduced endogenous level of dCBP in 
Drosophila may be due to competition for a limited pool of 
CBP protein, as in vertebrates a large number of transcription 
factors are known to use CBP as a co-activator. 
We have shown that the region downstream of the DNA-
binding domain in D-Myb binds to dCBP. Like the activation 
domain of mammalian c-Myb and A-Myb, this region con-
tains a region rich in acidic amino acids. Our domain analyses 
of D-Myb indicate that both the DNA binding and dCBP 
binding domains are necessary and sufficient for rrarcs-activa-
tion. This is similar to the case of mammalian A-Myb and 
c-Myb, but unlike that of B-Myb which requires an additional 
C-terminal conserved region for iraw-activation [15]. 
Although D-Myb also possesses this C-terminal conserved 
region, deletion of this region did not affect its ?ra«.j-activating 
capacity. D-Myb is also different from mammalian A-Myb 
and c-Myb with respect to the role of the C-terminal half of 
the molecule. Removal of a region downstream of the CBP-
binding domain in mammalian c-Myb and A-Myb increases 
their frans-activating activity [10,14], whereas deletion of a 
similar region in D-Myb did not affect frans-activating activ-
ity. In the case of c-Myb, the leucine zipper is located in the 
C-terminal proximal region, and disruption of this motif leads 
to increased activity [37]. However, D-Myb does not have the 
leucine zipper motif. In addition, the EVES motif in the C-ter-
minal region of c-Myb binds to the DNA-binding domain 
intramolecularly [38], but this EVES motif is not present in 
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D-Myb. Although these results suggest that the regulation of 
the mammalian Myb activity by the C-proximal region was an 
additional element acquired during evolution, we can not 
completely exclude that D-Myb activity is modulated by the 
C-proximal region under certain in vivo conditions. For in-
stance, c-Myb activity is known to be regulated by proline-
directed serine/threonine protein kinase [39], and the putative 
phosphorylation sites of this protein kinase are also present in 
the C-proximal region of D-Myb. Fur thermore, the modula-
tion of c-Myb activity by phosphorylation varies depending 
on the target promoter [40]. These results raise the possibility 
that D-Myb activity may also be affected by phosphorylation 
within the C-terminal domain depending on the nature of the 
target promoter . 
Recently, Drosophila myb mutants have been isolated. Ge-
netic analyses of these mutants indicated that D-myb is im-
por tant for both embryonic and imaginal development [41]. 
The system described here should be useful for the further 
study of the relationship between the biochemical character-
istics and functional activity of D-myb in vivo. 
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